Filtered By:
Condition: Bleeding
Education: Academia
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 422 results found since Jan 2013.
Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial
CONCLUSIONS: Although there was no significant interaction between sex and treatment effect of study drugs, the superior efficacy of prasugrel was more evident among men. No difference in bleeding between the two study groups was seen for both women and men.PMID:33867409 | DOI:10.5551/jat.62776
Source: Journal of Atherosclerosis and Thrombosis - April 19, 2021 Category: Cardiology Authors: Senta Gewalt Shqipdona Lahu Gjin Ndrepepa Costanza Pellegrini Isabell Bernlochner Franz-Josef Neumann Maurizio Menichelli Tanja Morath Bernhard Witzenbichler Jochen W öhrle Katharina Hoppe Gert Richardt Karl-Ludwig Laugwitz Heribert Schunkert Adnan Kastr Source Type: research
Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study
CONCLUSION: In contemporary PCI practice, nearly half of patients had HBR and presence of HBR significantly increased risk of ischemic/thrombotic events. Both aspirin and P2Y12 inhibitor monotherapy following short DAPT had low and comparable ischemic/bleeding events.PMID:33875313 | DOI:10.1016/j.jjcc.2021.03.015
Source: Journal of Cardiology - April 20, 2021 Category: Cardiology Authors: Hirofumi Hioki Ken Kozuma Yoshihisa Kinoshita Mamoru Nanasato Yoshiaki Ito Junichi Yamaguchi Nobuo Shiode Kiyoshi Hibi Kengo Tanabe Junya Ako Yoshihiro Morino Atsushi Hirohata Shinjo Sonoda Yoshihisa Nakagawa Hisayuki Okada Takuo Nakagami Itaru Takamisawa Source Type: research
Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial
CONCLUSIONS: Although there was no significant interaction between sex and treatment effect of study drugs, the superior efficacy of prasugrel was more evident among men. No difference in bleeding between the two study groups was seen for both women and men.PMID:33867409 | DOI:10.5551/jat.62776
Source: Journal of Atherosclerosis and Thrombosis - April 19, 2021 Category: Cardiology Authors: Senta Gewalt Shqipdona Lahu Gjin Ndrepepa Costanza Pellegrini Isabell Bernlochner Franz-Josef Neumann Maurizio Menichelli Tanja Morath Bernhard Witzenbichler Jochen W öhrle Katharina Hoppe Gert Richardt Karl-Ludwig Laugwitz Heribert Schunkert Adnan Kastr Source Type: research
Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study
CONCLUSION: In contemporary PCI practice, nearly half of patients had HBR and presence of HBR significantly increased risk of ischemic/thrombotic events. Both aspirin and P2Y12 inhibitor monotherapy following short DAPT had low and comparable ischemic/bleeding events.PMID:33875313 | DOI:10.1016/j.jjcc.2021.03.015
Source: Journal of Cardiology - April 20, 2021 Category: Cardiology Authors: Hirofumi Hioki Ken Kozuma Yoshihisa Kinoshita Mamoru Nanasato Yoshiaki Ito Junichi Yamaguchi Nobuo Shiode Kiyoshi Hibi Kengo Tanabe Junya Ako Yoshihiro Morino Atsushi Hirohata Shinjo Sonoda Yoshihisa Nakagawa Hisayuki Okada Takuo Nakagami Itaru Takamisawa Source Type: research
Analysis of individualized antiplatelet therapy for patients of acute coronary syndrome after percutaneous coronary intervention under the guidance of platelet function: A one-center retrospective cohort study
There is controversy in clinical application of antiplatelet drugs by monitoring platelet function. Therefore, we explored whether early and dynamic medication could bring better clinical outcomes for patients under the guidance of platelet function tests (PFT).
In this retrospective cohort study, we analyzed the prognostic events of 1550 patients with acute coronary syndrome (ACS) at Tianjin People's Hospital in China. They received dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) from January 2017 to December 2018. The primary endpoint was based on the Bleeding Academic Research Consorti...
Source: Medicine - April 23, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Interaction between thrombin potential and age on early clinical outcome in patients hospitalized for COVID-19
AbstractPatients with Coronavirus Disease-2019 (COVID ‐19) have haemostatic dysfunction and are at higher risk of thrombotic complications. Although age is a major risk factor for outcome impairment in COVID-19, its impact on coagulative patterns here is still unclear. We investigated the association of Endogenous Thrombin Potential (ETP) with thromb otic and haemorrhagic events according to different ages in patients admitted for COVID-19. A total of 27 patients with COVID‐19-related pneumonia, without need for intensive care unit admission or mechanical ventilation at hospital presentation, and 24 controls with non-C...
Source: Journal of Thrombosis and Thrombolysis - June 10, 2021 Category: Hematology Source Type: research
Clinical results and 30-day outcomes of self-expanding transcatheter aortic valves: comparative case-matched analysis of CoreValve < sup > ® < /sup > versus ACURATE neo ™
CONCLUSION: Both self-expandable prostheses showed good postoperative hemodynamic performance with a low incidence of severe paravalvular leakage, all- cause mortality, and comparable clinical outcomes.PMID:34472999 | DOI:10.1177/02676591211042562
Source: Perfusion - September 2, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Borko Ivanov Kaveh Eghbalzadeh Ilija Djordjevic Mohamed Zeriouh Stephen Gerfer Christopher Gaisendrees Anton Sabashnikov Christian Rustenbach Parwis Rahmanian Ferdinand Kuhn-Regnier Navid Mader Matti Adam Stephan Baldus Thorsten Wahlers Elmar Kuhn Source Type: research
P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
CONCLUSIONS: P2Y₁₂ inhibitor monotherapy, mostly clopidogrel, following 3 months of DAPT did not increase ischemic events in patients with complex PCIs.PMID:34523115 | DOI:10.5603/CJ.a2021.0101
Source: Cardiology Journal - September 15, 2021 Category: Cardiology Authors: Ji Woong Roh Joo-Yong Hahn Ju-Hyeon Oh Woo Jung Chun Yong Hwan Park Woo Jin Jang Eul-Soon Im Jin-Ok Jeong Byung Ryul Cho Seok Kyu Oh Kyeong Ho Yun Deok-Kyu Cho Jong-Young Lee Young-Youp Koh Jang-Whan Bae Jae Woong Choi Wang Soo Lee Hyuck Jun Yoon Seung Uk Source Type: research
